Once daily changes in early trading reasons : Shanghai Industrial Investment Co., Ltd. medicine to the current non-targeted public offerings of stock not total more than 10,722 20,000 (issue price of 14.13 yuan /股) which intends to actual controller Shanghai Industrial Holdings Limited, a wholly-owned subsidiary of the Company, is Medicine (Pakistan Forum) health products Limited number of shares issued in 6587 to 20,000. for the acquisition, holders of the real health Zhengda youth-Pharmaceutical Limited (registered capital of 128.5 million yuan) 55% equity , Hangzhou Huqingyu Hall Pharmaceutical Limited (registered capital of 53.16 million yuan) 51.0069% stake Xiamen Factory Limited (registered capital of 47.83 million yuan) 61% stake Liaoning good nurses Pharmaceutical (Group) Co., Ltd. (registered capital of 51 million yuan) on the 55% equity and is holding wholly-owned subsidiary of Win-held by the Investment Company Huqingyu Hall Experiences in next Hangzhou, Ltd. 29% shareholding. These assets The total value of about 1.515 billion yuan. Investment Highlights : a company focused on the development of biomedical industry, medical equipment subsidiary of Shanghai Industrial and Shanghai Kehua biological (Pakistan Forum) technology companies have maintained a good level of profitability; acquisition of the Guangdong Temple biochemical pharmaceutical companies 51% stake Guangdong Temple is the current domestic production of urine protein products one of the largest manufacturers. 2, a major shareholder, is expected to continue to be controlled under the Pharmaceutical quality of assets, will be integrated into the company to make a medicine (Pakistan Forum) assets platform. Within this total, the youthful-medicine Zhengda Company Limited (Holdings is holding 55%), Chinese enterprises is the largest one, the most advanced equipment to natural medicine as the main raw material integrated pharmaceutical enterprises, with an annual sales volume of 1.2 billion yuan scale. 11 Chinese products entering the country to protect species, into the country's basic medical insurance drug list with 36. Also, Shanghai 3D Biotechnology Company Ltd., the holder is holding 70.4% interest, the SEG production of injection, cancer chemotherapy drug support for the state's key new products. Risk Tip : domestic pharmaceutical industry market competition even more severe, more stringent intellectual property protection. for a company created by the operation of certain difficulties. Investment proposals : Shanghai as companies set up overseas in the largest and strongest integrated enterprise groups for a long time in biomedicine, business-networking industry, the textile industry and the traditional manufacturing industry in many areas, including both the spoils; From the long view, the unit has some investment value. Recommendation tracking monitor. 1st goal-22 a copy.